Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2024-07-15 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司第十届监事会第五次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of a supervisory board meeting resolution, specifically about the resignation of a supervisor and the proposal to elect a new supervisor. It includes details about the meeting attendance, voting results, and references a related announcement. The content focuses on changes in the company's board of supervisors, which falls under management or board information. The document is short (557 characters) and does not contain financial data or detailed reports. Therefore, it is classified as Board/Management Information (MANG).
2024-07-15 Chinese
江苏四环生物股份有限公司第十届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding the approval to convene an extraordinary general meeting (EGM). It includes details about the board meeting, attendance, and voting results. There is no financial data, audit information, or detailed report content. It is not a full report but an announcement of a board decision. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2024-07-15 Chinese
江苏四环生物股份有限公司2024年半年度业绩预告
Regulatory Filings Classification · 95% confidence The document is a performance forecast for the half-year period ending June 30, 2024, indicating expected losses and providing preliminary estimated financial figures. It explicitly states that the forecast is unaudited and that the final data will be in the 2024 half-year report. The document length is short (720 characters), and it serves as an announcement of expected financial results rather than a full interim or quarterly report containing actual financial statements. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement of performance forecast, not the full interim report itself.
2024-07-09 Chinese
江苏四环生物股份有限公司关于实际控制人部分股份被司法再冻结的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the judicial re-freezing of shares held by the actual controller and other shareholders of the company. It details the number of shares frozen, the proportion of shares affected, and the legal reasons behind the freezing. There is no financial data, earnings information, or management discussion. The document is a regulatory announcement about shareholding restrictions due to legal actions, not a financial report or earnings release. It fits best under Regulatory Filings (RNS) as it is a compliance disclosure about share freezes and legal status of shares.
2024-06-12 Chinese
江苏四环生物股份有限公司关于实际控制人部分股份被司法再冻结的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Sihuan Bio Co., Ltd. regarding the judicial re-freezing of shares held by the actual controller and related shareholders. It details the number of shares frozen, the proportion of shares affected, and the legal reasons for the freeze. The document does not contain financial statements, management discussion, or detailed financial data. It is a regulatory announcement about shareholding status and legal actions affecting shares, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2024-06-11 Chinese
江苏四环生物股份有限公司关于拟为控股子公司申请银行授信额度提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. regarding the company's board resolution to provide a guarantee for a bank credit line application by its controlling subsidiary. It details the guarantee amount, the subsidiary's financial status, and the board's opinion on the guarantee. The document is an announcement of a corporate financing-related decision, specifically about providing a guarantee for bank credit, which falls under capital or financing updates. It is not a full financial report, audit, or earnings release, nor is it a regulatory filing or management report. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and content support this classification with high confidence.
2024-06-07 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.